Maintenance therapy with peginterferon Alfa-2b does not prevent hepatocellular carcinoma in cirrhotic patients with chronic hepatitis C

Gastroenterology

Volumn 140, Issue 7, 2011, Pages 1990-1999

  Bruix, Jordi ^a   Poynard, Thierry ^b   Colombo, Massimo ^c   Schiff, Eugene ^d   Burak, Kelly ^e   Heathcote, Elizabeth J L ^f   Berg, Thomas ^g   Poo, Jorgeluis ^h   Mello, Carlos Brandao ⁱ   Guenther, Rainer ^j   Niederau, Claus ^k   Terg, Ruben ^l   Bedossa, Pierre ^m   Boparai, Navdeep ⁿ   Griffel, Louis H ⁿ   Burroughs, Margaret ⁿ   Brass, Clifford A ⁿ   Albrecht, Janice K ⁿ  

^a UNIVERSITY OF BARCELONA   (Spain)

^b SORBONNE UNIVERSITÉ   (France)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF CALGARY   (Canada)

^f UNIVERSITY OF TORONTO   (Canada)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h LIVER RESEARCH UNIT   (Mexico)

ⁱ FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^j UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^k St Josef Hospital Oberhausen   (Germany)

^l Capital Federal ^*  (Argentina)

^m BEAUJON HOSPITAL   (France)

ⁿ MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Clinical Trial; Evaluation of PegIntron in Control of Hepatitis C Cirrhosis Program; Liver Cancer

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; COLCHICINE; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALOPECIA; ANTIVIRAL THERAPY; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BLEEDING; BRAIN DISEASE; CANCER GROWTH; CANCER PREVENTION; CARDIOVASCULAR DISEASE; CONTROLLED STUDY; COUGHING; DECOMPENSATED LIVER CIRRHOSIS; DEPRESSION; DIARRHEA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TREATMENT FAILURE; ESOPHAGUS VARICES; FATIGUE; FEMALE; FEVER; FLU LIKE SYNDROME; HAZARD RATIO; HEPATITIS C; HUMAN; HYPERTENSION; INFECTION; INJECTION SITE ERYTHEMA; INSOMNIA; IRRITABILITY; LIVER CANCER; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FAILURE; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; NAUSEA; NEUTROPENIA; NEUTROPHIL COUNT; OPEN STUDY; PNEUMONIA; PORTAL HYPERTENSION; PRIORITY JOURNAL; PROSPECTIVE STUDY; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RASH; SEPSIS; SEPTIC SHOCK; SIDE EFFECT; SPLENOMEGALY; SUICIDAL IDEATION; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT RESPONSE; UPPER ABDOMINAL PAIN; VIRUS LOAD;

EID: 79958177731     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2011.03.010     Document Type: Article

References (23)

1. D. Lavanchy The global burden of hepatitis C Liver Int 29 2009 74 81
2. World Health Organization Hepatitis C http://www.who.int/mediacentre/ factsheets/fs164/en/print.html Accessed February 27, 2006
3. S. Maylin, M. Martinot-Peignoux, and R. Moucari Eradication of hepatitis C virus in patients successfully treated for chronic hepatitis C Gastroenterology 135 2008 821 829
4. S. Bruno, A. Crosignani, and C. Facciotto Sustained virologic response prevents the development of esophageal varices in compensated, Child-Pugh class A hepatitis C virus-induced cirrhosis A 12-year prospective follow-up study Hepatology 51 2010 2069 2076
5. T. Poynard, J. McHutchison, and M. Manns Impact of pegylated interferon alfa-2b and ribavirin on liver fibrosis in patients with chronic hepatitis C Gastroenterology 122 2002 1303 1313 (Pubitemid 34465173)
6. S. Nishiguchi, T. Kuroki, and S. Nakatani Randomised trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1995 1051 1055
7. Anonymous Effect of interferon-α on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study International Interferon-α Hepatocellular Carcinoma Study Group Lancet 351 1998 1535 1539
8. H. Toyoda, T. Kumada, and S. Nakano Effect of the dose and duration of interferon-α therapy on the incidence of hepatocellular carcinoma in noncirrhotic patients with a nonsustained response to interferon for chronic hepatitis C Oncology 61 2001 134 142 (Pubitemid 32786207)
9. K. Ikeda, S. Saitoh, and M. Kobayashi Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study J Gastroenterol Hepatol 16 2001 406 415 (Pubitemid 32397653)
10. D.-C. Valla, M. Chevallier, and P. Marcellin Treatment of hepatitis C virus-related cirrhosis: a randomized, controlled trial of interferon α-2b versus no treatment Hepatology 29 1999 1870 1875 (Pubitemid 29247063)
11. V. Baffis, I. Shrier, and A.H. Sherker Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection Ann Intern Med 131 1999 696 701 (Pubitemid 29517956)
12. H. Tanaka, H. Tsukuma, and A. Kasahara Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients Int J Cancer 87 2000 741 749 (Pubitemid 30620419)
13. J. Bruix, and M. Sherman Management of hepatocellular carcinoma Hepatology 42 2005 1208 1236 (Pubitemid 43112690)
14. T. Poynard, M. Colombo, and J. Bruix Peginterferon alfa-2b and ribavirin: effective in patients with hepatitis C who failed interferon alfa/ribavirin therapy Gastroenterology 136 2009 1618 1628.e2
15. International Conference on Harmonisation Expert Working Group International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use ICH Harmonised Tripartite Guideline. Guideline for Good Clinical Practice E6 (R1) International Conference on Harmonisation Steering Committee; 1996:1-59. E6 (R1) http://www.ich.org/ fileadmin/Public-Web-Site/ICH-Products/Guidelines/Efficacy/E6-R1/Step4/ E6-R1-Guideline.pdf Accessed April 26, 2011
16. Afdhal N, Levine R, Brown R Jr, et al. Colchicine versus peginterferon alfa 2b long-term therapy: results of the 4 year COPILOT trial (oral presentation). Presented at: 43rd Annual Meeting of the European Association for the Study of the Liver; April 23-27, 2008; Milan, Italy.
17. R. de Franchis Evolving consensus in portal hypertension Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension J Hepatol 43 2005 167 176 (Pubitemid 40805288)
18. Y. Miyake, Y. Iwasaki, and K. Yamamoto Meta-analysis: reduced incidence of hepatocellular carcinoma in patients not responding to interferon therapy of chronic hepatitis C Int J Cancer 127 2009 989 996
19. A.M. Di Bisceglie, M.L. Shiffman, and G.T. Everson Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon N Engl J Med 359 2008 2429 2441
20. R.J. Fontana, A.J. Sanyal, and M.G. Ghany Factors that determine the development and progression of gastroesophageal varices in patients with chronic hepatitis C Gastroenterology 138 2010 2321 2331
21. A.S. Lok, J.E. Everhart, and E.C. Wright Maintenance peginterferon therapy and other factors associated with hepatocellular carcinoma in patients with advanced hepatitis C Gastroenterology 140 2011 840 849
22. D.C. Rockey Hepatic fibrosis, stellate cells, and portal hypertension Clin Liver Dis 10 2006 459 479 (Pubitemid 44879987)
23. T. Ogawa, N. Kawada, and K. Ikeda Effect of natural interferon alpha on proliferation and apoptosis of hepatic stellate cells Hepatol Int 3 2009 497 503